[{"command":"settings","settings":{"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxFytEKgCAMRuEXMn2k-GsrB9PG0nr9IMIuz8fh5bKmlKRewnfgLwuTYJKCnYcZHLvD8lQOgs4rnMI7pk20sccV1uSoYZxnIu8Gjb_EXq0vKmdmegDh4DCV","theme":"ebvptld","theme_token":null},"ajaxTrustedUrl":[],"user":{"uid":0,"permissionsHash":"4867837929d82f46a0b8d631cb1b853ab572e5989466da9ff30f538d13a4af8e"}},"merge":true},{"command":"add_css","data":[{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_zFE0GntIr5sJtoaw0onuR1rz-A25LT_DlBnsJ-mCx8I.css?delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"},{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_rp-nJs0EOjtUdAxu7hbmuIO3NIwEYbwhfB4JNT82dPg.css?delta=1\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"}]},{"command":"add_js","selector":"body","data":[{"src":"\/sites\/default\/files\/js\/js_fgI_F9T9iHdlscNdB1Tqblhfn81ETkj65lf7riv4k8o.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxLzi9K1U8pKi1IzNFLyUzMyU_XS8xKrNBJTSorKMlJ0c_MK8tMLYdzyyuLM8sr0wE6xBUe"}]},{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\n  \u003Cdiv id=\u0022p244\u0022 class=\u0022js-inview paragraph paragraph--type--modal-card paragraph--view-mode--teaser modal wysiwyg\u0022\u003E\n         \n  \u003Cp class=\u0022title-h3\u0022\u003EPTLD-2 MODIFIED RSST STUDY\u003Csup\u003E19\u003C\/sup\u003E\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular\u0022\u003E\u003Cstrong\u003EModified RSST\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular\u0022\u003EA Phase 2 trial tested a modified RSST approach. In addition to patients who achieved a CR after rituximab induction, rituximab maintenance monotherapy was also given to those in PR and who were considered low risk with \u0026lt;3 IPI risk factors.\u0026nbsp;\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular\u0022\u003E\u003Cstrong\u003ESimilar TTP, OS and PFS were observed vs PTLD-1 ST and RSST trials.\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u0026nbsp;\u003C\/p\u003E\n\u003Cdiv class=\u0022row\u0022 style=\u0022align-items:center;margin:0 -1.2rem;\u0022\u003E\n\u003Cdiv class=\u0022study2GraphWrapper flex\u0022\u003E\n\u003Cdiv class=\u0022column\u0022\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E\u003Cstrong\u003EPRIMARY ENDPOINT\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E2-year EFS KM estimate in the low-risk group was\u0026nbsp;\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E66%(95%, CI 45\u201386)\u003C\/span\u003E\u003Cbr\u003E\u0026nbsp;\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E\u003Cstrong\u003ETIME TO PROGRESSION\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E\u003Cstrong\u003E78%\u003C\/strong\u003E progression-free at 2 years (ITT population)\u003C\/span\u003E\u003C\/p\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study2-graph1.png?itok=A78nS16L\u0022 width=\u0022700\u0022 height=\u0022377\u0022 alt loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003E\u003Cstrong\u003EStudy design\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022e52e7a813a7fe0a6c37c65b8a30d8a1c2\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EProspective, multicentre, open-label phase 2 trial tested modified risk-stratification in adult SOT recipients (N=60) with CD20-positive PTLD based on principles established in the PTLD-1 trials: sequential treatment and risk-stratification\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e2dc90ce454ade897abca7575c27b5fdf\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EFollowing rituximab monotherapy induction:\u0026nbsp;\u003C\/span\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022e0b605a37f1e76006ff3cbed8f150cb06\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EPatients in CR or PR with IPI \u0026lt;3 (low risk), continued rituximab monotherapy only\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e065c34a5dd1319b391224be2da45c905\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EMost remaining patients (high risk) received R-CHOP-21\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ea39b0dea50951a52b6fffbf52072e5ea\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EThoracic SOT recipients who progressed (very high risk) were treated with alternating R-CHOP-21 and modified R-DHAOx\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ed43fec134d79d09bb38ef17bb1e6315b\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EMedian follow-up, 2.8 years\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e42484e09e82b5b014e261586c7174658\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EPrimary endpoint: event-free survival in the low-risk group\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022column\u0022\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E\u003Cstrong\u003ESURVIVAL\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular text-white\u0022\u003E\u003Cstrong\u003E68%\u003C\/strong\u003E OS at 2 years (ITT population)\u003C\/span\u003E\u003C\/p\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study2-graph2.png?itok=6NktuuqJ\u0022 width=\u0022700\u0022 height=\u0022385\u0022 alt loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003E\u003Cstrong\u003EAdverse events\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022e9689f1afc5c6566fa22d780570901f8c\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EGrade 3\/4 infections in 42% of patients\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e6eb68f557e1d35bfac5fcf66aa580635\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EGrade 3\/4 leukopenia in 37% of patients\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e797f0110acf6c7aa47cc9166d350dbf1\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003E7% experienced CHOP-associated treatment-related mortality\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e00c22e98f497dcd2fad36f2ad166c453\u0022\u003E\u003Cspan class=\u0022smallish text-white\u0022\u003EOther frequent grade 3\/4 AEs included anaemia, thrombocytopenia, acute renal failure and gastrointestinal haemorrhage\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cstrong\u003EPooled analysis of low-risk groups in PTLD-1 and PTLD-2 (N=58)\u003C\/strong\u003E\u003C\/p\u003E\n\u003Cdiv class=\u0022row\u0022 style=\u0022align-items:center;margin:0 -1.2rem;\u0022\u003E\n\u003Cdiv class=\u0022study2GraphWrapper noBackground flex\u0022\u003E\n\u003Cdiv class=\u0022column\u0022\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study2-graph3.png?itok=KLfTVeZx\u0022 width=\u0022800\u0022 height=\u0022445\u0022 alt loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cspan class=\u0022small\u0022\u003E*PTLD-2 trial; \u003Csup\u003E\u2020\u003C\/sup\u003EThirty-seven patients from PTLD-1 RSST; five patients from PTLD-2.\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022column\u0022\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study2-graph4.png?itok=t6ky37Cb\u0022 width=\u0022800\u0022 height=\u0022448\u0022 alt loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cspan class=\u0022small\u0022\u003EAdapted in colour from Zimmermann H, et al. Leukemia. 2022. https:\/\/creativecommons.org\/licenses\/by\/4.0\/.\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\n\n      \u003C\/div\u003E\n","dialogOptions":{"width":"60%","modal":true,"title":""}}]